TECH STOCKS TREND
IBM AND NOVO NORDISK TO CREATE ARTIFICIAL INTELLIGENCE FOR INSULIN DOSAGE ACCOUNTANCY
December 13, 2015 By Delbert Lawson 0 62
With advancement in technology, medical notion of “every disease is curable” is seeing further foresight. As per latest reports, Novo Nordisk is having a partnership with IBM Watson Health to come up with a virtual window to diabetes patients that could be able to dispense treatment advice like insulin dosage.
IBM’s Watson was recognized in year 2011 for processing vast amounts of information to spot patterns and answer queries. That accomplishment further made International Business Machines Corporation to develop Watson Heath sector this year. Likewise, Novo Nordisk isn’t the first to apply the platform to health care. In year 2012, one of the earlier adopters was New York’s Memorial Sloan Kettering Cancer Center, which claimed to be working with IBM Watson in development of a tool that could help oncologists in drawing on huge amounts of clinical data for cancer diagnose and treatment. on a similar note, recently Johnson & Johnson has partnered with IBM Watson Health to develop a virtual coach for people who had undergone knee-replacement surgery.
The Danish diabetes specialist hopes to use IBM’s supercomputer platform, IBM’s Watson, to analyze health data from diabetes patients to help them manage their disease.
“Data from continuous blood-sugar monitors that upload readings to the Internet could be analyzed and used to inform treatment decisions.” – Novo Nordisk’s Executive vice president, Jakob Riis
In order to develop a wider perspective into an insight of food intake and insulin dosage, an artificial intelligence can provide a better source of data for evaluation. Amid project objectives is a one that deals with more data evaluation comprising food intake, accurate information on the timings of insulin injection dosage and exercise of a body.
A union between IBM Watson Health and Novo Nordisk could bring about a collection of real-world data on patients using its drugs, which in turn could be used to strengthen its hand in negotiations with payers. However, financial details of the partnership have not yet been disclosed to the press.